anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIM: To investigate the association between pericoronary adipose tissue (PCAT) attenuation (PCATA) and outcomes of chronic total occlusion (CTO) after percutaneous coronary intervention (PCI), and to establish a clinical model that can be easily generalised to predict the outcomes of PCI-CTO.
MATERIALS AND METHODS: Between September 2015 and September 2019, patients from two centres were enrolled retrospectively. The primary endpoint was a procedural success (defined as achieving residual stenosis of <30% and a grade 3 thrombolysis in myocardial infarction [TIMI] flow). The new predictive model was generated by factors that were determined by multivariate analysis. The PCATA of CTO (PCATA-CTO) score was developed by assigning 1 point for each independent predictor, and then summing all points accrued. In addition, the predictive efficacy and interobserver and intraobserver agreement of PCATA-CTO and other scoring systems based on coronary computed tomography angiography (CCTA) were compared.
RESULTS: A total of 201 patients (mean age 58.9 ± 10.8 years, 85% male) were enrolled. The PCI success was achieved in 76% of the lesions. PCAT was higher in the PCI success group (-72.44 ± 10.45HU versus -76.76 ± 10.54 HU, p<0.05). Multivariable analysis yielded severe calcification, lesion length ≥15 mm, and perivascular fat attenuation index (FAI) ≤-69.5HU as independent negative predictors for procedural success. The area under the receiver operating characteristic curves for the PCATA-CTO score was 0.72. Comparing the PCATA-CTO score with other predictive scores, the PCATA-CTO score showed the highest interobserver (kappa = 0.74) and intraobserver agreement (kappa = 0.90, all p<0.01).
CONCLUSION: FAI ≤-69.5HU is an independent negative predictor of procedural success. The PCATA-CTO score improved the reliability of the prediction model. Its potential for clinical implementation requires evaluation.
This will be a pilot, proof-of-concept study. Patients 60 years or older with invasively proven HFpEF or have definite HFpEF as determined by the 2 established scores and frailty (positive screen for computable phenotype), will be approached for enrollment. Subjects meeting screening criteria following written informed consent will be randomized to receive rapamycin or matching placebo (study drug). Efficacy outcomes will be measured at baseline and at 6 months. Safety will be assessed by in person or remote video monitoring weekly for 1 month, then monthly for 5 months till the end of the study. We will also measure trough rapamycin levels (≤4ng/mL) twice-a-month for the first month and then monthly for 5 months.
BACKGROUND: Surgery for thoracic disc herniations remains an ongoing challenge, with numerous surgical approaches, all with their own inherent risks. Discectomy via a posterior laminectomy was historically the treatment of choice; however, it was deemed very high risk with elevated rates of neurologic injury. The posterior transdural approach is an alternative surgical option for soft and calcified thoracic disc herniations.
METHODS: A 56-year-old female with many years of numbness/tingling in her hands and difficulty with fine motor tasks presented with progressive weakness and loss of balance in her legs. Imaging revealed a prominent focal central calcified disc herniation at the T5-T6 level causing severe effacement and distortion of the spinal cord. A posterior transdural approach for direct visualization of a large calcified disc herniation was performed, removing the calcified disc without the need for extensive exposure or entry into the thoracic cavity. A ventral sling of the dura was created to allow rotation of the spinal cord while removing the disc.
RESULTS: Intraoperative ultrasound confirmed complete disc resection, restoring cerebral spinal fluid flow circumferentially without residual impingement or cerebrospinal fluid leaks. At six months postsurgery, the patient's gait imbalance had resolved, and she had full lower extremity strength (5/5). Radiographic evaluation indicated stable implants without subsidence, pullout, fracture, or alignment loss.
CONCLUSIONS: The transdural approach is less invasive in nature, minimizes surgical exposure, patient morbidity, and provides better intraoperative control of the spinal cord. This constitutes an effective alternative surgical approach to both soft and calcified central thoracic disc herniations.
Compounds, compositions and methods for the diagnosis of Alzheimer's disease. Synthesized Glycerophosphocholine (GPC) may be used as a diagnostic aid to measure progression of Alzheimer's disease. GPC is a membrane phospholipid metabolite that is capable of binding specifically to the β-turn of beta amyloid (Aβ) peptide. Compounds including non-radioactive, paramagnetic, and radioactive derivatives of GPC are presented. These compounds possess similar binding properties to original GPC molecules and are useful in medical magnetic resonance imaging and/or positron emission tomography applications. By employing these radiological techniques in conjunction with the compositions of the present invention, the diagnosis and assessment of the progression of Alzheimer's disease may be achieved.
In the United States there were 38,900 cases and 12,840 deaths from renal cell carcinoma in 2006. Renal cell carcinoma represents 2% of all cancers worldwide. The majority of kidney tumors are discovered incidentally during investigation of unrelated complaints. However, nearly 30% of patients present with metastatic disease at the time of diagnosis and 30-40% of patients with clinically localized kidney cancer will have a recurrence. The diagnosis and monitoring of kidney cancer requires expensive and frequent imaging examinations. There is a significant need to find diagnostic and prognostic biomarkers to screen, diagnose, and monitor renal cancers.

A reliable urinary assay for kidney cancer would have major implications for tumor screening in high risk patients, in selection of patients for adjuvant therapy, in surveillance and prognosis and possibly as a surrogate marker for response to therapy. Human kidney injury molecule-1 (KIM-1) has been found to be a sensitive and specific biomarker in identifying kidney injury. The urine levels of KIM-1 are increased in the patients with kidney failure and major types of kidney tumors. The purpose of the study is investigate how urine KIM-1 and a routine blood marker for renal failure (creatinine) can distinguish kidney tumors from non-tumor kidney injury. The ultimate goal of this project is to develop a simple non-invasive method to screen patients for potential kidney tumors.
A new natural oil personal care composition and system for treating damaged hair and/or supporting healthy hair and healthy hair growth. The composition comprises a blend of natural oils including Jamaican black castor oil, and one or more of natural sweet almond oil (preferably unrefined), pure avocado oil, and hemp seed oil (preferably unrefined). The oils are preferably organic. The composition is useful for repairing damaged, depleted and/or thinning hair due to various factors, including inadequate nutrition or overproduction of sebum, which can result in hair loss. The composition is also useful for repairing dry, frizzy, oily, dull (low shine), and brittle hair that has been naturally damaged by the elements (e.g. the sun, heat, wind, and/or cold), by wearing head gear or hair accessories that create friction with the hair surface (e.g. helmets, hair elastics and hair bands), by inappropriate or overuse use of hair styling tools (e.g. hair dryers, curling and straightening irons), and/or by chemical processes (e.g. hair dyes, perms, chemical straighteners, chemotherapies).
PROBLEM TO BE SOLVED: To obtain an emulsion powder which includes an oil-soluble substance and a cell containing oil particles stable to shock and is free from permeation of oil on tabletting by adding an oil-soluble substance and a processed starch to water to emulsify followed by drying. SOLUTION: This emulsion powder is obtained by adding (B) an oil-soluble substance, (C) a processed starch and (D), when necessary, a vegetable gum (e.g. gum arabic) into (A) water to emulsify followed by drying the resultant emulsion. As the component B, edible oils and fats, e.g. medicines, health foods or the like, are preferably used. In the concrete, vitamin E, docosahexaenoic acid or the like is preferably used. As the component C, an ester between starch and an organic acid, e.g. an alkenylated succinic acid (e.g. octenylsuccinic acid) or the like, having emulsifying effect is favorable. The emulsion powder is the product obtained by aggregation of many particles (cells) that the component B of core substance is coated with the component C or the like. It is suitable that the particle size is 50-500 μm.
Peritoneal adhesion typically occurs in applications such as abdominal, pelvic, and vascular surgery. It is necessary to develop a mechanical barrier to prevent adhesion. In this study, a novel biomaterial as a mechanical barrier is developed by combining polyvinyl alcohol (PVA) and carboxymethyl cellulose (CMC), doped with polyhedral oligomeric silsesquioxane (POSS) to prevent peritoneal adhesion. Fourier-transform infrared spectroscopy (FTIR) and X-ray diffraction (XRD) methods reveal that POSS nanoparticles in the PVA matrix disrupted the intramolecular hydroxyl groups and structure of the crystal region. Electron microscopy (EM) images reveal that high concentrations of POSS (2 wt.%) cause irregular clustering in the composite matrix. As the concentration of POSS increases in the matrix, the degradation of the membranes increases, and protein adhesion decreases. In vitro cytotoxicity tests show a toxic effect on cells for PVA/CMC composite membranes, while on the other hand, the addition of POSS increases cell viability. According to the MMT test the POSS decreases cell adhesion of membranes. When comparing the POSS doped membrane to the undoped PVA/CMC membrane, an increase in the total antioxidant level and a decrease in the total oxidant level is observed.
Most newly diagnosed oropharyngeal and hypopharyngeal cancers are treated with radiochemotherapy with curative intent. If the field-set UP margins are broad, the consequence may be that quality of life is impaired. The study group of Nutting et al. (2023) investigated this year whether dysphagia-optimized intensity-modulated radiotherapy can reduce the radiation dose to structures associated with dysphagia and aspiration and improve swallowing function compared to standard IMRT (Nutting C, Finneran L, Roe J, Petkar I, Rooney K, Hall E; DARS Triallist Group. Dysphagia-optimized intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer - Authors' reply. Lancet Oncol. 2023 Oct;24(10):e398. doi: 10.1016/S1470-2045(23)00457-6. PMID: 37797636.) The study group concluded that the results suggest that dysphagia-optimized IMRT improves patient-reported swallowing function compared to standard IMRT. DO-IMRT should be considered the new standard of care for patients receiving radiotherapy for pharyngeal cancer, and ART could further improve outcomes.

Thus, in this trial we analyze ART in head and neck cancer in a prospective randomized trial.
Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.
The invention provides new methods of treatment using anti-scarring agents to inhibit scarring in humans, and also provides anti-scarring agents for new uses in the inhibition of scarring in humans. In a first incidence of treatment an anti-scarring agent is provided to each centimetre of a wound margin or each centimetre of a site at which a wound is to be formed in a first therapeutically effective amount; and in a subsequent incidence of treatment the anti-scarring agent is provided to each centimetre of wound margin in a larger therapeutically effective amount. The incidences of treatment occur between 8 hours and 48 hours apart from one another. The anti-scarring agent is preferably not TGF-.beta.3.  The anti-scarring agent may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound.
The invention provides a polypeptide composition for promoting skin microcirculation and application thereof. The polypeptide composition consists of carnosine and palmitoyl pentapeptide-4. Wherein the mass ratio of carnosine to palmitoyl pentapeptide-4 is (1:4) - (4:1). The effective dosage range of the polypeptide composition is 10 mu g/mL-2000 mu g/mL. Compared with a cooling skin feel regulator, the polypeptide composition can increase the content of the skin acetylcholine or inhibit the thrombin activity in skin microvasculature, thereby really achieving the effect of promoting skin microcirculation. Compared with the natural extract, the polypeptide composition has definite composition components and no redundant impurities, avoids hidden skin allergy caused by complex components of the natural extract or residual impurities such as solvents, heavy metals and the like caused by the industrial extraction process, and greatly reduces the risk of toxic and side effects on human bodies. Compared with natural extract, the polypeptide composition has small addition amount in cosmetic or skin external medicine preparation, and can promote skin microcirculation.
Obesity is an important healthcare issue caused by abnormally increased adipose tissue because of energy-intake overcoming energy expenditure. Disturbances in the physiological function of adipose tissue mediate the development of diabetes. It is a metabolic disease that results from decreased insulin-levels and/or changes in the insulin action mechanism. Tumor Necrosis Factor-Associated Apoptosis-Inducing Ligand(TRAIL), which is a member of the Tumor Necrosis Factor(TNF)-family with an important role in adipose tissue biology, is included in many studies with its ability to induce apoptosis in cancer cells, but the number of human-studies conducted on the gene related to its protective-role against diabetes and obesity at this level is insufficient. Our study was carried out as a case and control and included three groups (80 diabetic obese, 80 non-diabetic obese, and 80 healthy individuals as the control group). The Real-Time-PZR(RT-qPZR), and DNA Sanger-Sequencing Methods were used for gene expression and gene squences. As a result of the analyses, TRAIL gene expression level was found to be higher in the controls than in the diabetic-obese and non-diabetic-obese group. This change in TRAIL gene expression suggests that TRAIL maybe a protective factor against diabetes. The presence of rs781673405, rs143353036, rs1244378045, rs767450259, rs759369504, rs750556128, and rs369143448 mutations, which was determined with the Sequencing-Method, was shown for the first time in the present study. In addition, it is the first study in which human TRAIL gene-expression and sequencing were performed together. We believe that these data will make an important contribution to the literature.
An emulsion base suitable as an ointment or salve base or as a starting material in the manufacture of cosmetics, comprises an admixture of hydrogenated glyceride, a wool wax alcohol or alcohols, and a natural or synthetic ester or esters of such alcohol with or without other ingredients.  Suitable hydrogenated glycerides are wholly or partially hydrogenated castor, arachis, olive, palm kernel, cotton seed, soya-bean, cocoanut and sesame oils.  Wool wax alcohols include cholesteral, agnosterol, lanosterol, and other alcohols obtained by the hydrolysis of wool wax.  The natural esters include anhydrous lanoline while suitable synthetic esters are the oleate or stearate.  Suitable additional ingredients include liquid hydrocarbon oils such as light mineral spindle oil, white oil or liquid paraffin, natural petroleum jelly or a mixture of hard paraffin with light mineral oil.  Water may also be added to produce aqueous emulsions especially in the form of pastes or salves.
The invention discloses a method for removing hepatotoxicity in a blue-green-blue-green ethanol water extract, which can be used for more safely treating human diseases. The hepatotoxicity-removing extracts provided can be formulated into pharmaceutical compositions and medicaments useful in the disclosed methods. This combination, after removal of chlorophyll, hepatotoxicity and significant ineffective fractions thereof by the method of the invention, increases the effective content of the active compound relatively significantly. Because of the removal of toxic components, it is possible to use higher effective doses to improve the therapeutic effect. The removal of chlorophyll, hepatotoxicity and significant inactive fractions from aqueous extract of brevibrasol by the process of the invention results in a relatively significant increase in the active compound content. Because the toxic components are removed, the corresponding curative effect of the aleppo avens extract can be improved by applying higher effective dose.
The increased incidence of invasive pulmonary aspergillosis, caused by Aspergillus fumigatus, occurring in patients infected with severe influenza or SARS-CoV-2, suggests that antiviral immune responses create an environment permissive to fungal infection. Our recent evidence suggests that absence of the type I IFN receptor 2 subunit (IFNAR2) of the heterodimeric IFNAR1/2 receptor is allowing for this permissive immune environment of the lung through regulation of damage responses. Because damage is associated with poor outcome to invasive pulmonary aspergillosis, this suggested that IFNAR2 may be involved in A. fumigatus susceptibility. In this study, we determined that absence of IFNAR2 resulted in increased inflammation, morbidity, and damage in the lungs in response to A. fumigatus challenge, whereas absence of IFNAR1 did not. Although the Ifnar2-/- mice had increased morbidity, we found that the Ifnar2-/- mice cleared more conidia compared with both wild-type and Ifnar1-/- mice. However, this early clearance did not prevent invasive disease from developing in the Ifnar2-/- mice as infection progressed. Importantly, by altering the inflamed environment of the Ifnar2-/- mice early during A. fumigatus infection, by neutralizing TNF-α, we were able to reduce the morbidity and fungal clearance in these mice back to wild-type levels. Together, our results establish a distinct role for IFNAR2 in regulating host damage responses to A. fumigatus and contributing to an A. fumigatus-permissive environment through regulation of inflammation. Specifically, our data reveal a role for IFNAR2 in regulating TNF-α-mediated damage and morbidity during A. fumigatus infection.
Participants will undergo 12-16 weeks of GnRH analog, along with 8-12 weeks of combinational therapy with GnRH analog and abiraterone plus prednisone. 14 participants who achieve \>75% PSA decline after the run-in period will be enrolled. GnRH analog and abiraterone will be stopped after study enrollment. PSA and testosterone level will be measured every 4 weeks during the run-in period, then every 6 weeks after study enrollment. Imaging studies with CT and bone scan will be performed at the time of study enrollment and these will be considered baseline scans. Study treatment will be restarted if participant's PSA reaches 2 fold or higher of his baseline PSA. Selection of treatment will be based on participant's testosterone level.
In adult patients with beta thalassemia, thromboembolic events (TEE) were reported in 8/223 (3.6%) REBLOZYL-treated patients. Reported TEEs included deep vein thromboses, pulmonary embolus, portal vein thrombosis, and ischemic strokes. Patients with known risk factors for thromboembolism, e.g. splenectomy or concomitant use of hormone replacement therapy, may be at further increased risk of thromboembolic conditions. Consider thromboprophylaxis in patients with beta thalassemia at increased risk of TEE.

Monitor patients receiving REBLOZYL for signs and symptoms of thromboembolic events and institute treatment promptly.
High-quality training and networking are pivotal for enhancing the research capacity of early- to mid-career researchers in the prevention and control of non-communicable diseases. Beyond building research skills, these professionals gain valuable insights from interdisciplinary mentorship, networking opportunities, and exposure to diverse cultures and health systems. Despite the significance of such initiatives, their implementation remains underexplored. Here, we describe the implementation and evaluation of the Excellence in Non-COommunicable disease REsearch (ENCORE) program, a collaborative initiative between Australia and India that was launched in 2016 and spanned a duration of 3 years. Led by a consortium that included the University of Melbourne and leading Indian research and medical institutions, ENCORE involved 15 faculty members and 20 early-mid career researchers. The program comprised various elements, including face-to-face forums, masterclasses, webinars, a health-technology conference, and roundtable events. ENCORE successfully trained the early-career researchers, resulting in over 30 peer-reviewed articles, 36 conference presentations, and the submission of seven grant applications, three of which received funding. Beyond individual achievements, ENCORE fostered robust research collaboration between Australian and Indian institutions, showcasing its broader impact on strengthening research capacities across borders.
The fibromyalgia syndrome is a chronic condition with widespread pain that poses a great challenge for patients, rheumatologists and society because of the lack of optimal treatment options. There is extensive evidence that, in comparison with patients with rheumatoid arthritis, fibromyalgia patients report higher levels of functional disability, pain, fatigue, and lower levels of quality of life. Although effectiveness of pharmacological agents and other interventions is generally limited, most promising effects have been found for non-pharmacological treatments, particularly those with a primary focus on cognitive-behavioral treatment components. However, also these treatment outcomes are characterized by large individual variation. Particularly patients with less impairments in daily life seem to benefit less from these treatments. In line with the international literature, previous findings of the research group suggest that effectiveness might be increased when tailored cognitive-behavioural treatments are solely offered to patients at risk.

In the present project the effects of tailored interventions based on cognitive-behavioral factors for patients at risk are studied. In a randomized, controlled trial, fibromyalgia patients are screened for risk profiles. Patients at risk will be assigned to tailored cognitive or behavioral treatment conditions, depending on their risk profile with respect to cognitive-behavioral factors. Half of the patients are subsequently randomly assigned to a waiting list control condition. It is expected that this tailored treatment approach will increase magnitude and maintenance of treatment effects for pain, disability, fatigue and increased quality of life, which means an important step forward for patients, involved professionals and society.
Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth. Participants receive a 12 session job readiness training with linkages to businesses and employment opportunities. Discussions include a wide range of topics related to career exploration and job readiness.
Group C (control group): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.